ADA Virtual Meeting Will Offer 5 Symposia on Latest COVID-19 Findings

The upcoming American Diabetes Association (ADA) virtual 81st Scientific Sessions will feature 5 COVID-19 Symposia highlighting the latest science and diabetes developments learned during the initial phases of the pandemic.

The COVID-19 Symposia will be presented over the course of the annual meeting, being held June 25-29, 2021.

“This past 16 months elevated the need for diabetes awareness and care in a turbulent way, as diabetes ranks as one of the top risk factors for severe complications from COVID-19. Seeing the devastating impact of the pandemic on people with diabetes, the ADA is emboldened to work even harder to lead the fight against diabetes. Our mission is reinforced by researchers from around the globe committed to closely studying specific impacts and interventions to help people living with diabetes during this COVID-19 era,” ADA Chief Scientific & Medical Officer Robert Gabbay, MD, PhD, said in an ADA press release. “We look forward to displaying this in five comprehensive symposia to help share key learnings and set the groundwork for how we treat patients moving forward.”

Each session of the symposium will highlight the effect of COVID-19 on diabetes care, with topics ranging from treatment of COVID-19 long-haulers, to addressing COVID-19 and health disparities, obesity, telehealth, and mental health among patients with diabetes.

There will also be a live Q&A held after each session for media and conference attendees to speak with the lead researchers.

The 5 sessions are as follows:

• Friday, June 25, 2:00–3:45 pm ET: COVID-19 and Diabetes—An Update
• Saturday, June 26, 8:00-9:25 am ET: ADA Diabetes Care Symposium—Learning to Minimize Risks for People with Diabetes in the COVID-19 Pandemic
• Sunday, June 27, 2:15-3:45 pm ET: Efficacy and Safety of Dapagliflozin in Patients with and without Type 2 Diabetes Hospitalized with COVID-19— Results from the DARE-19 Global Randomized Controlled Trial
• Sunday, June 27, 4:30-6:30 pm ET: Efficacy and Safety of Dapagliflozin in Patients with and without Type 2 Diabetes Hospitalized with COVID-19— Results from the DARE-19 Global Randomized Controlled Trial
• Monday, June 28, 4:30-6:30 pm ET: COVID-19, Diabetes, and Obesity

In addition to the COVID-19 Symposia, the ADA will host a press event on Monday, June 28, 2021 at 7:00 pm ET discussing COVID-19 and diabetes.